FYB203

About Formycon AG

Formycon AG is a Germany-based, publicly traded biopharmaceutical company with a strategic focus on developing and commercializing biosimilars and next-generation biologics. The company has successfully transitioned to a commercial-stage entity, with key biosimilars like FYB201 (ranibizumab) approved in Europe, and has secured significant commercial partnerships for its pipeline. Its strategy centers on a robust in-house development platform, strategic licensing deals with global partners for commercialization, and a pipeline targeting high-value immunology and oncology biologics. Formycon aims to create sustainable value by increasing access to affordable biologic medicines while navigating the complex biosimilar regulatory and market landscape.

Therapeutic Areas

Other Ophthalmology (nAMD, DME, RVO) Drugs